New Developments in Retinal Pharmacotherapy

Intravitreal Interventions: Volume 8, Number 1

Intravitreal Interventions: Volume 8, Number 1

Unprecedented growth has occurred over the past few years in the diagnosis…

Expiration Date: 6/27/2020

Max Credits: 1

View Activity

Clinical Impact of Protocol T: 2-year Data

Clinical Impact of Protocol T: 2-year Data

Intravitreal pharmaceuticals have become the mainstay for retinal therapy.…

Expiration Date: 3/28/2018

Max Credits: 0

View Activity

Intravitreal Interventions: Volume 5, Number 3

Intravitreal Interventions: Volume 5, Number 3

Intravitreal pharmaceuticals have become the mainstay for retinal therapy.…

Expiration Date: 9/29/2017

Max Credits: 0

View Activity

Intravitreal Interventions: Volume 5, Number 2

Intravitreal Interventions: Volume 5, Number 2

Intravitreal pharmaceuticals have become the mainstay for retinal therapy.…

Expiration Date: 7/28/2017

Max Credits: 0

View Activity

Intravitreal Interventions: Volume 5, Number 1

Intravitreal Interventions: Volume 5, Number 1

Intravitreal pharmaceuticals have become the mainstay for retinal therapy.…

Expiration Date: 6/6/2017

Max Credits: 0

View Activity

Intravitreal Interventions – Volume 3, Number 1

Intravitreal Interventions – Volume 3, Number 1

Intravitreal pharmacotherapy, including long-acting corticosteroids, anti-…

Expiration Date: 6/15/2015

Max Credits: 0

View Activity

Potential Role of Aflibercept as the Next VEGF Antagonist in the Management of Diabetic Macular Edema

Potential Role of Aflibercept as the Next VEGF Antagonist in the Management of Diabetic Macular Edema

Several treatment strategies have been used to halt or decelerate disease …

Expiration Date: 10/31/2014

Max Credits: 0

View Activity

Combination Anti-VEGF and Dexamethasone Therapy for Macular Edema Associated with Retinal Venous Occlusions

Combination Anti-VEGF and Dexamethasone Therapy for Macular Edema Associated with Retinal Venous Occlusions

Retinal vein occlusion (RVO) is the second most common type of retinal vas…

Expiration Date: 10/31/2014

Max Credits: 0

View Activity

Ranibizumab in the Management of Diabetic Macular Edema: Where Do We Stand in 2013?

Ranibizumab in the Management of Diabetic Macular Edema: Where Do We Stand in 2013?

Diabetic macular edema (DME) is a primary cause of vision loss in the work…

Expiration Date: 10/31/2014

Max Credits: 0

View Activity

Early Experience Using Aflibercept in the Treatment of Wet Macular Degeneration

Early Experience Using Aflibercept in the Treatment of Wet Macular Degeneration

The approval of aflibercept by the US Food and Drug Administration in Nove…

Expiration Date: 12/1/2013

Max Credits: 0

View Activity